Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma

Inclusion Criteria: * Patient must understand, be willing to give consent, and sign a written informed consent form prior to undergoing any study-specific procedure * Male or female and ≥ 18 years of age * Metastatic or non-resectable adeno- or squamous-cell carcinoma of the stomach or oesophagus who failed on first line cytotoxic treatment with a fluoropyrimidine and platinum compound * Tumor accessible for repeated biopsies * Measurable or evaluable disease * Life expectancy of at least 12 weeks * Eastern Cooperative Oncology Group performance status of 0 or 1 * Have adequate bone marrow, liver function, and renal function as measured by pre-specified laboratory assessments conducted within 7 days prior to the start of study treatment * If female and of childbearing potential, have a NEGATIVE result on a pregnancy test performed a maximum of 7 days before start of study treatment * If female and of childbearing potential or if male, must agree to use adequate contraception based on the judgment of the investigator or a designated associate from the date on which the ICF is signed until 6 months after the last dose of study drug. Exclusion Criteria: * Prior treatment with regorafenib * Contra-indications for repeated biopsies * Dementia or altered mental status that would prohibit the understanding and giving of informed consent * Inadequate caloric- and/or fluid intake. * Pre-existing motor or sensory neurotoxicity greater than WHO grade 1 * Have unresolved toxicity higher than National Cancer Institute-Common Terminology for Adverse Events version 4.0 (NCI-CTCAE v 4.0) Grade 1 attributed to any prior therapy/procedure, excluding alopecia. * Have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of study treatment * If female and of childbearing potential, be engaged in breast feeding * Be unable to swallow oral tablets * Have congestive heart failure classified as New York Heart Association Class 2 or higher * Have had unstable angina or new-onset angina ≤ 3 months prior to screening * Have had a myocardial infarction ≤ 6 months prior to start of study treatment * Have cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin * Have uncontrolled hypertension despite optimal medical management * Have pheochromocytoma * Have had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 3 months prior to the initiation of study treatment * Have an ongoing infection ≥ Grade 2 (NCI-CTCAE v 4.0) * Have a known history of human immunodeficiency virus infection * Have either active hepatitis B or C or chronic hepatitis B or C requiring treatment * Have a seizure disorder requiring medication * Have currently suspected brain metastases * Have a history of organ allograft * Have evidence or history of any bleeding diathesis (including mild hemophilia), irrespective of severity * Have had a hemorrhage or a bleeding event \> Grade 3 ( NCI-CTCAE v 4.0) within 4 weeks prior to the start of study treatment * Have a non-healing wound, ulcer, or bone fracture * Have interstitial lung disease with ongoing signs and symptoms at the time informed consent is obtained * Have any other serious illness or medical condition that could jeopardize the safety of the patient * Have an unstable illness or medical condition that could jeopardize the safety of the patient and/or his/her compliance * Have a substance abuse, medical, psychological, or social condition that may interfere with participation in the study or evaluation of the study results * Have a known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs * Have any malabsorption condition * Using and unable to stop medication that are prohibited due to interaction * Unwilling to stop pommelos, citrus fruit and herbal medicine inducing or inhibiting the CYP system